P2RX1 antibodies are monoclonal or polyclonal reagents that bind to the P2RX1 receptor (UniProt ID: P51575 in humans), a protein encoded by the P2RX1 gene. This receptor facilitates ATP-mediated calcium and sodium ion flux across cell membranes and is implicated in processes like platelet activation, smooth muscle contraction, and immune modulation .
C-terminal domain: Targeted by Alomone Labs’ APR-001 (amino acids 382–399 in rats) .
Extracellular domain: Recognized by FITC-conjugated antibodies (e.g., APR-022-F) .
P2RX1’s functions span multiple systems:
Reproductive Health: Essential for normal male fertility in mice .
Immune Regulation: Modulates neutrophil infiltration and intestinal inflammation .
Cancer Biology: Correlates with immune cell infiltration and prognosis in breast and pancreatic cancers .
P2RX1 antibodies are validated for:
P2RX1 is upregulated in IBD patients and promotes neutrophil-driven inflammation .
Key Finding: Combining a P2RX1 inhibitor (e.g., NF449) with anti-TNF-α therapy enhances efficacy in murine colitis models .
Breast Cancer: Low P2RX1 expression correlates with poor prognosis and reduced immune infiltration (B cells, CD8+ T cells) .
Pancreatic Cancer: P2RX1-deficient neutrophils foster immunosuppressive microenvironments, accelerating metastasis .
P2RX1 ablation reduces DSS-induced colitis severity by suppressing neutrophil infiltration and reshaping gut microbiota .
In pancreatic cancer, P2RX1-negative neutrophils promote PDAC liver metastasis via PD-1/CTLA-4 upregulation .
Immune Checkpoints: P2RX1 expression positively correlates with PD-1, CTLA-4, and PD-L1 in breast cancer .
Microbiota Interaction: P2RX1 deficiency activates the AhR/IL-22 axis, altering microbial metabolites in colitis .